Drug targeting systems for inflammatory disease: One for all, all for one

JOURNAL OF CONTROLLED RELEASE

卷:161

Review

Crielaard, Bart J.¹  Lammers, Twan^2,3  Schiffelers, Raymond M.^1,4  Storm, Gert^1,3 

[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci UIPS, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands

[2] Rhein Westfal TH Aachen, Dept Expt Mol Imaging, Aachen, Germany

[3] Univ Twente, Dept Targeted Therapeut, NL-7500 AE Enschede, Netherlands

[4] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands

关键词: Drug targeting;    Nanomedicine;    Inflammatory disease;    Rheumatoid arthritis;    Multiple sclerosis;   

DOI  :  10.1016/j.jconrel.2011.12.014

来源: Elsevier

【 摘 要 】

In various systemic disorders, structural changes in the microenvironment of diseased tissues enable both passive and active targeting of therapeutic agents to these tissues. This has led to a number of targeting approaches that enhance the accumulation of drugs in the target tissues, making drug targeting an attractive strategy for the treatment of various diseases. Remarkably, the strategic principles that form the basis of drug targeting are often employed for tumor targeting, while chronic inflammatory diseases appear to draw much less attention. To provide the reader with a general overview of the current status of drug targeting to inflammatory diseases, the passive and active targeting strategies that have been used for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS) are discussed. The last part of this review addresses the dualism of platform technology-oriented (one for all) and disease-oriented drug targeting research (all for one), both of which are key elements of effective drug targeting research. (C) 2012 Elsevier B.V. All rights reserved.

【 授权许可】

Free